Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (325)	8/11/2003 5:48:05 PM
From: Ian@SI	Respond to of 824

That I can completely agree with. But that's not new. It's just another argument for diversification. (re Individual being the very last to know)

To: keokalani'nui who wrote (325)	8/11/2003 11:51:15 PM
From: Madharry	Read Replies (2) \| Respond to of 824

Perhaps someone could tell me: when the company sets up a phase III do they not have to file documents with the FDA as to the precise primary endpoints and secondary endpoints are prior to obtaining the results? are these documents accessible by the public? if so how? Because if what MZ is conjecturing that the CABG plus valve result was some minor secondary endpoint, which is how i interpret what he is saying, then what Bell said at the conference call was misleading to say the least. If MZ is correct in what he is implying then we have to look at that 25% vs. 30% and how does the FDA look at that- are we saying that 30% is statistically significant and 25% is not?